Ovareline 50 mikrogram/ml Injektionsvätska, lösning İsveç - İsveççe - Läkemedelsverket (Medical Products Agency)

ovareline 50 mikrogram/ml injektionsvätska, lösning

ceva santé animale - gonadorelindiacetattetrahydrat - injektionsvätska, lösning - 50 mikrogram/ml - bensylalkohol hjälpämne; gonadorelindiacetattetrahydrat 58 mikrog aktiv substans - nöt

Tyljet 200 mg/ml Injektionsvätska, lösning İsveç - İsveççe - Läkemedelsverket (Medical Products Agency)

tyljet 200 mg/ml injektionsvätska, lösning

ceva santé animale - tylosin - injektionsvätska, lösning - 200 mg/ml - tylosin 200 mg aktiv substans; propylenglykol hjälpämne; bensylalkohol hjälpämne - nöt, svin

Firodyl vet 250 mg Tuggtablett İsveç - İsveççe - Läkemedelsverket (Medical Products Agency)

firodyl vet 250 mg tuggtablett

ceva santé animale - firocoxib - tuggtablett - 250 mg - firocoxib 250 mg aktiv substans; laktosmonohydrat hjälpämne - hund

Firodyl vet 62,5 mg Tuggtablett İsveç - İsveççe - Läkemedelsverket (Medical Products Agency)

firodyl vet 62,5 mg tuggtablett

ceva santé animale - firocoxib - tuggtablett - 62,5 mg - firocoxib 62,5 mg aktiv substans; laktosmonohydrat hjälpämne - hund

Tulaven Avrupa Birliği - İsveççe - EMA (European Medicines Agency)

tulaven

ceva santé animale - tulatromycin - antibakteriella medel för systemisk användning - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. förekomsten av sjukdomen i besättningen bör fastställas före metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. förekomsten av sjukdomen i besättningen bör fastställas före metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling av de tidiga stadierna av infektiös pododermatit (fotrot) i samband med virulent dichelobacter nodosus som kräver systemisk behandling.

Vectormune FP ILT + AE Avrupa Birliği - İsveççe - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kyckling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Cevac MD Rispens Koncentrat och vätska till injektionsvätska, suspension İsveç - İsveççe - Läkemedelsverket (Medical Products Agency)

cevac md rispens koncentrat och vätska till injektionsvätska, suspension

ceva-phylaxia veterinary biologicals co. ltd. - kycklingherpesvirus, stam cvi-988, levande försvagat - koncentrat och vätska till injektionsvätska, suspension - dimetylsulfoxid hjälpämne; kycklingherpesvirus, stam cvi-988, levande försvagat 800 - 5000 pfu aktiv substans; sackaros hjälpämne; sorbitol hjälpämne - fjäderfä

Enteroporc Coli Avrupa Birliği - İsveççe - EMA (European Medicines Agency)

enteroporc coli

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - immunologiska medel för suidae - grisar - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Enteroporc Coli AC Avrupa Birliği - İsveççe - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - grisar - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Ultifend ND IBD Avrupa Birliği - İsveççe - EMA (European Medicines Agency)

ultifend nd ibd

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals för aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).